Alivus Life Sciences (NSE:ALIVUS) Institutional Ownership: 6.42% (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ALIVUS Alivus Life Sciences Ltd NSE:ALIVUS
80 GF Score
Price ₹1,335.80
GF Value ₹1,028.11
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Alivus Life Sciences Institutional Ownership?

Alivus Life Sciences NSE:ALIVUS +10.00% 80 Institutional Ownership is 6.42% as of Aug. 05, 2026. GuruFocus rates NSE:ALIVUS with a GF Score™ of 80/100 and a GF Value™ of ₹1,028.11 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alivus Life Sciences's institutional ownership is 6.42%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alivus Life Sciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alivus Life Sciences's Float Percentage Of Total Shares Outstanding is 0.00%.

Alivus Life Sciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Alivus Life Sciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alivus Life Sciences Institutional Ownership Chart

Alivus Life Sciences Historical Data

The historical data trend for Alivus Life Sciences can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 6.74 6.37 6.23 6.21 6.26 6.40 6.49 6.50 6.41 6.42
NSE:ALIVUS
80GF Score
Alivus Life Sciences Ltd NSE:ALIVUS
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alivus Life Sciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 6.42% mean?
Alivus Life Sciences (NSE:ALIVUS) has a Institutional Ownership of 6.42% as of Aug. 05, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Alivus Life Sciences and its competitors.
Is Alivus Life Sciences' Institutional Ownership too high?
Alivus Life Sciences' current Institutional Ownership is 6.42%. Overall, Alivus Life Sciences has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Institutional Ownership compare to ZTS?
Alivus Life Sciences' Institutional Ownership of 6.42% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Alivus Life Sciences and its competitors. Alivus Life Sciences's current Institutional Ownership is 6.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,028.11, compared to a current price of ₹1,335.80 — trading 29.9% above its estimated fair value. The current Institutional Ownership is 6.42%. Alivus Life Sciences' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Institutional Ownership is 6.42% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?

Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued. The current stock price of ₹1,335.80 is trading 29.9% above its estimated GF Value™ of ₹1,028.11. GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.

Key valuation signals for NSE:ALIVUS:

  • Institutional Ownership: 6.42%
  • GF Value™: ₹1,028.11 vs. price of ₹1,335.80 (29.9% above fair value)
  • GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alivus Life Sciences Business Description

Other Exchanges 543322:India
Address 470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
80GF Score

Get the complete analysis for NSE:ALIVUS

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,335.80
Price
₹1,028.11
GF Value